With CE mark approval, the pulsed field ablation procedure becomes available to treat patients in Europe with persistent ...
Company also elevates Jeff O’Donnell, Sr. to executive chairman and moves polymer processing in-house to new local manufacturing facility as it reaches critical inflection point PITTSBURGH--(BUSINESS ...
11d
Pulse Biosciences targets CE Mark submission in 2026 as nPulse platform advances clinical milestones
Q4 2025 earnings call: nsPFA clinical/regulatory timeline, Vybrance rollout, revenue trends, cash burn & outlook—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results